Raras
Buscar doenças, sintomas, genes...
Glioma das vias ópticas
ORPHA:2086CID-10 · D33.3CID-11 · 2A02.0YDOENÇA RARA

O glioma das vias ópticas (GVO) é um tumor benigno (não-canceroso) que cresce no nervo óptico e nas suas "extensões" (partes como o quiasma, os tratos e as radiações, que formam todo o caminho da visão até o cérebro). Ele é caracterizado por causar problemas ou a perda da visão, e também pode vir junto com outros sintomas, como um crescimento mais lento e alterações no sono. Esses últimos sintomas estão ligados a uma parte específica do cérebro. O GVO é frequentemente associado à neurofibromatose tipo 1 (NF1), uma condição genética.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

O glioma das vias ópticas (GVO) é um tumor benigno (não-canceroso) que cresce no nervo óptico e nas suas "extensões" (partes como o quiasma, os tratos e as radiações, que formam todo o caminho da visão até o cérebro). Ele é caracterizado por causar problemas ou a perda da visão, e também pode vir junto com outros sintomas, como um crescimento mais lento e alterações no sono. Esses últimos sintomas estão ligados a uma parte específica do cérebro. O GVO é frequentemente associado à neurofibromatose tipo 1 (NF1), uma condição genética.

Pesquisas ativas
5 ensaios
42 total registrados no ClinicalTrials.gov
Publicações científicas
421 artigos
Último publicado: 2026 Apr 13
Medicamentos
5 registrados
ETOPOSIDE, DOXORUBICIN, IRINOTECAN

Tem tratamento?

5 medicamentos registrados
Ver detalhes, fases e interações →
ETOPOSIDEDOXORUBICINIRINOTECANIRINOTECAN HYDROCHLORIDESELUMETINIB

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D33.3
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
8 sintomas
🧠
Neurológico
5 sintomas
🫃
Digestivo
2 sintomas
📏
Crescimento
2 sintomas
💪
Músculos
1 sintomas

+ 5 sintomas em outras categorias

Características mais comuns

55%prev.
Atrofia óptica
Frequente (79-30%)
55%prev.
Nistagmo
Frequente (79-30%)
55%prev.
Acuidade visual reduzida
Frequente (79-30%)
55%prev.
Neurofibromas
Frequente (79-30%)
55%prev.
Perda visual
Frequente (79-30%)
17%prev.
Oftalmoplegia
Ocasional (29-5%)
23sintomas
Frequente (5)
Ocasional (18)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 23 características clínicas mais associadas, ordenadas por frequência.

Atrofia ópticaOptic atrophy
Frequente (79-30%)55%
NistagmoNystagmus
Frequente (79-30%)55%
Acuidade visual reduzidaReduced visual acuity
Frequente (79-30%)55%
Neurofibromas
Frequente (79-30%)55%
Perda visualVisual loss
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico421PubMed
Últimos 10 anos200publicações
Pico202240 papers
Linha do tempo
2026Hoje · 2026🧪 1992Primeiro ensaio clínico📈 2022Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 210
1Fase 19
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 5 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Glioma das vias ópticas

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

42 ensaios clínicos encontrados, 5 ativos.

Distribuição por fase
NCT01089101 · Selumetinib in Treating Young Patients With Recurrent or Ref…Ativo
PHASE1, PHASE2
NCT03871257 · A Study of the Drugs Selumetinib Versus Carboplatin/Vincrist…Ativo
PHASE3
NCT05733572 · Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6…Ativo
PHASE2
NCT00638898 · Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cel…Concluído
PHASE1
NCT01553149 · Low-Dose or High-Dose Lenalidomide in Treating Younger Patie…Concluído
PHASE2
NCT03326388 · Intermittent Dosing Of Selumetinib In Childhood NF1 Associat…Concluído
PHASE1, PHASE2
NCT02780804 · Entinostat in Treating Pediatric Patients With Recurrent or …Concluído
PHASE1
NCT02415153 · Pomalidomide in Treating Younger Patients With Recurrent, Pr…Concluído
PHASE1
NCT00919750 · Collecting and Storing Blood and Brain Tumor Tissue Samples …Concluído
NCT00003477 · Antineoplaston Therapy in Treating Children With Visual Path…Concluído
PHASE2
NCT01260103 · Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Gliom…Cancelado
PHASE3
NCT02194452 · Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) …Cancelado
NA
NCT02175745 · 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients …Encerrado
NA
NCT00326664 · AZD2171 in Treating Young Patients With Recurrent, Progressi…Concluído
PHASE1
NCT01088763 · Gamma-Secretase Inhibitor RO4929097 in Treating Young Patien…Encerrado
PHASE1
NCT00929903 · Pazopanib Hydrochloride in Treating Young Patients With Soli…Concluído
PHASE1
NCT00012181 · Flavopiridol in Treating Children With Relapsed or Refractor…Concluído
PHASE1
NCT00994500 · Vorinostat and Bortezomib in Treating Young Patients With Re…Concluído
PHASE1
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥇Melhor nível de evidência: Revisão sistemática
Timeline de publicações
299 papers (10 anos)
#1

Differences in Optic Pathway Glioma Prevalence among Children with Neurofibromatosis Type 1.

The Journal of pediatrics2026 Mar 17

This multi-institutional, natural language processing-based analysis of 273 children with neurofibromatosis 1-associated optic pathway gliomas examines the impact of ancestral background on clinical presentation and progression. We report that White children had higher OPG prevalence than Black or Asian children, but clinical features and outcomes did not differ across groups.

#2

Central Precocious Puberty and Optic Pathway Glioma in Children with Neurofibromatosis 1: Associations with Tumor Location, Vision, and Treatment.

The Journal of pediatrics2026 Mar 02

Neurofibromatosis 1-associated optic pathway gliomas (OPGs) may co-occur with central precocious puberty (CPP). Using large language model-based data analysis from 2 NF centers, we compared OPGs in children with NF1, with and without CPP. CPP was associated with hypothalamic involvement, poorer vision, and a higher likelihood of OPG treatment.

#3

Frontotemporal-orbitozygomatic approach for pediatric cranio-orbital tumors: a single-center experience.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026 Mar 23

To evaluate the surgical anatomy, technical nuances, and early postoperative outcomes of the frontotemporal-orbitozygomatic (FTOZ) approach in a consecutive series of pediatric cranio-orbital communicating tumors. To evaluate the surgical anatomy, technical nuances, and early postoperative outcomes of the frontotemporal-orbitozygomatic (FTOZ) approach in a consecutive series of pediatric cranio-orbital communicating tumors. Unilateral Dodge Class I Optic Pathway Glioma without Neurofibromatosis Type 1 (OPG-uDCI) was selected as an index pathology to illustrate the specific application of this approach in a representative subgroup. Thirteen children (five female, eight male) with imaging and histopathology confirmed cranio-orbital communicating tumours were managed at a single institution from April 2020 to August 2024. At operation, the median age was 24 months (interquartile range 4-156 months). Postoperative surveillance extended for a median of 21 months (interquartile range 9-62 months). Notably, 10 patients had a follow-up period of at least 12 months. Histopathological diagnoses included: OPG, rhabdomyosarcoma, mature teratoma, optic nerve sheath meningioma, langerhans cell histiocytosis, and ewing-like sarcoma. Surgical complications included one case of severe postoperative chemosis with corneal ulceration requiring enucleation and one wound infection. There were no operative mortalities in this series. During follow-up, no patients with OPG demonstrated contralateral visual field changes postoperatively. Among the seven participants in whom macroscopic total excision was accomplished, neoplastic relapse subsequently developed in three. The FTOZ approach is a technically feasible corridor for resection of pediatric cranio-orbital tumors in selected cases. However, given the small sample size, short follow-up, and occurrence of major complications, these findings should be considered preliminary. Definitive conclusions regarding safety and efficacy await larger comparative studies.

#4

Using Optical Coherence Tomography in Pediatric Neuro-ophthalmology.

International ophthalmology clinics2026 Apr 01

Optical coherence tomography (OCT) has transformed adult neuro-ophthalmology, but pediatric adoption has lagged because of perceived technical, financial, and practical barriers. This chapter provides a pragmatic framework for integrating OCT into pediatric and pediatric neuro-ophthalmology clinics, emphasizing how to obtain reliable images in awake children and how to interpret them. We first review technical aspects of tabletop and handheld OCT in children, including positioning, fixation strategies, and when to prioritize single-line macular or optic nerve head B-scans over full segmented protocols. We then outline key clinical modalities: single-line foveal scans for "in vivo histology" and ganglion cell layer/inner nuclear layer (GCL/INL) ratio screening; single-line optic nerve head (ONH) scans to assess Bruch membrane contour and opening size; ONH cube maps for papilledema versus pseudopapilledema; macular cube maps with segmentation to detect retinotopic patterns of GCL loss; and strategies to correct RNFL interpretation for axial length. Using a structured table-based approach, we show how combined RNFL and GCL measurements narrow the differential diagnosis and guide urgency and systemic workup in children with decreased vision and normal, swollen, or atrophic optic nerves. Disease-focused sections illustrate OCT applications in papilledema, pseudopapilledema, optic neuritis, neuroretinitis, optic pathway glioma, optic atrophy (including INL microcysts), infantile nystagmus, and congenital optic nerve anomalies. Throughout, we highlight pitfalls such as pseudonormalization of the RNFL, segmentation errors in high-grade edema or anomalous discs, and misinterpretation in highly ametropic eyes. The chapter aims to make OCT a routine, child-friendly extension of the neuro-ophthalmic exam.

#5

Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes.

Children (Basel, Switzerland)2026 Jan 24

Background/Objectives: Diencephalic syndrome (DS) is an uncommon pediatric disorder presenting with severe failure to thrive despite adequate caloric intake and preserved linear growth. First characterized by Russell, this condition predominantly affects infants under 12 months and remains diagnostically challenging. Methods: We performed a comprehensive literature review examining clinical presentation, underlying pathophysiology, associated pathology, diagnostic approaches, and long-term outcomes of DS. Results: DS typically manifests in the first year of life with profound cachexia, normal or increased appetite, preserved height velocity, and characteristic features including hyperactivity, euphorism, and visual pathway involvement. Low-grade gliomas of the hypothalamic-chiasmatic region, particularly pilocytic astrocytomas, represent the predominant underlying pathology. The pathophysiological mechanisms remain incompletely understood but likely involve complex dysregulation of hypothalamic energy homeostasis. While overall survival exceeds 90% at five years, most patients experience significant long-term morbidity including visual impairment, multiple endocrine deficiencies, and hypothalamic obesity. Diagnostic delays averaging 11 months contribute to irreversible complications. Conclusions: Early recognition of DS is essential to prevent permanent visual loss and optimize outcomes. Multidisciplinary management incorporating chemotherapy as first-line treatment for underlying gliomas has improved survival while reducing radiation-associated toxicities. However, survivors face substantial lifelong sequelae requiring comprehensive monitoring and intervention. Future research should focus on elucidating precise pathophysiological mechanisms, developing targeted molecular therapies, and improving management of hypothalamic obesity and other late effects.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC211 artigos no totalmostrando 198

2026

Frontotemporal-orbitozygomatic approach for pediatric cranio-orbital tumors: a single-center experience.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

Using Optical Coherence Tomography in Pediatric Neuro-ophthalmology.

International ophthalmology clinics
2026

Differences in Optic Pathway Glioma Prevalence among Children with Neurofibromatosis Type 1.

The Journal of pediatrics
2026

Central Precocious Puberty and Optic Pathway Glioma in Children with Neurofibromatosis 1: Associations with Tumor Location, Vision, and Treatment.

The Journal of pediatrics
2026

Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes.

Children (Basel, Switzerland)
2025

Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.

Neuro-oncology advances
2026

Midkine as a therapeutic node in NF1-driven neuro‑oncology: Biology, biomarkers, and translational strategies.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2025

Radiotherapy Utilization and Treatment Continuity of Pediatric Patients With Brain Tumor in Egypt: A Decade of Data.

JCO global oncology
2025

Protein domain-specific genotype-phenotype correlation study of neurofibromatosis type 1.

Scientific reports
2025

Exploring Optic Glioma and Type 1 Neurofibromatosis: A Literature Review of Case Reports.

Neuro-ophthalmology (Aeolus Press)
2026

Including visual outcomes in optic pathway glioma clinical trials.

Neuro-oncology
2025

Quantitative assessment of the corneal subbasal nerve plexus in children with neurofibromatosis type 1 and optic pathway glioma using in vivo confocal microscopy.

Scientific reports
2025

Prevalence of optic pathway glioma in NF1: a systematic review and meta-analysis focused on MRI surveillance.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2025

Bevacizumab in Pediatric Neuro-Oncology.

Current oncology (Toronto, Ont.)
2025

The effect of treatment with somatostatin analogs in children with neurofibromatosis type 1 and growth hormone excess.

Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
2025

Optic Pathway Glioma: Current Treatment Approaches and Ongoing Clinical Trials.

Brain sciences
2025

Endocrine manifestations in a paediatric cohort of 181 patients with neurofibromatosis type 1.

European journal of endocrinology
2025

Correlation between retinal nerve fibre layer thickness and tumour volume in patients with optic pathway gliomas.

International ophthalmology
2025

MRI-based, three-dimensionally assessed tumor burden and growth velocity to predict visual acuity deterioration in optic pathway glioma - results of a retrospective longitudinal analysis.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2025

Opsoclonus in Children: Diagnosis, Etiology, and Ophthalmologic Assessment of Patients at a Tertiary Children's Hospital.

Pediatric neurology
2025

Fractionated Gyroscopic Radiosurgery for Optic Nerve Glioma: A Case Report and Review of the Literature.

Cureus
2025

Growth hormone excess in children with neurofibromatosis and optic pathway glioma, an underdiagnosed condition: experience with long-acting treatment.

European journal of endocrinology
2024

A Rare Case of Sporadic Optic Pathway Glioma in a 7-year-old Female.

Kathmandu University medical journal (KUMJ)
2025

Neuroimaging and Metabolic Features of Optic Pathway Glioma in a Child with Neurofibromatosis Type 1: Low-Grade Glioma Transformation in the Left Optic Radiation.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
2025

Impact of Optic Pathway Gliomas on Puberty and Growth in Neurofibromatosis Type 1: A 20-Year Experience From a Tertiary Center.

Journal of child neurology
2025

Severe sleep-wake disturbances in a patient with rapidly progressive optic pathway glioma.

Sleep medicine
2025

Supra-sellar clear cell ependymoma in a 2-year-old female: A case report.

International journal of surgery case reports
2025

Predictors in Optic Pathway Gliomas in Neurofibromatosis Type 1: A Single Center Study.

Cancers
2025

A rare presentation of pediatric germinoma mimicking optic pathway glioma: illustrative case.

Journal of neurosurgery. Case lessons
2025

Ocular Safety and Visual Acuity Stability in Pediatric Patients With Optic Pathway Gliomas and Orbital Plexiform Neurofibromas Treated With BRAF and MEK Inhibitors.

Pediatric blood &amp; cancer
2025

Identifying patients with neurofibromatosis type 1 related optic pathway glioma using the OMOP CDM.

European journal of medical genetics
2025

A Retrospective, Nationwide, Multicenter Study on Diagnosis and Treatment Outcome of Pediatric Optic Pathway/Hypothalamic Gliomas Including Analysis of Risk Factors for Progression After Systemic Anticancer Therapy.

Cancers
2025

Visual outcome including visual field defects after treatment of paediatric optic pathway glioma: A nationwide cohort study.

Acta ophthalmologica
2025

Neurofibromatosis Type 1 (NF1)-Related Ocular Signs: New Insights on Their Prevalence, Incidence, and Genotype-Phenotype Correlation in NF1 Children.

American journal of ophthalmology
2025

Malignant Peripheral Nerve Sheath Tumor (MPNST) Arising from Orbital Plexiform Neurofibroma in a Small Child With Neurofibromatosis Type 1.

Cancer diagnosis &amp; prognosis
2025

Freiburg Neuropathology Case Conference: Progressive Optic Nerve Lesion Over a 16-Year Period.

Clinical neuroradiology
2025

Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review.

Seminars in nuclear medicine
2025

The efficacy and safety of Bevacizumab-based treatments in Optic Pathway Glioma among pediatric population: a systematic review and meta-analysis.

Neurosurgical review
2025

CONCURRENT OCCURRENCE OF NEUROFIBROMATOSIS TYPE 1 AND TURNER SYNDROME: A PEDIATRIC CASE REPORT WITH COMPREHENSIVE LITERATURE REVIEW.

Acta endocrinologica (Bucharest, Romania : 2005)
2025

Retinoblastoma and beyond: pediatric orbital mass lesions.

Neuroradiology
2025

Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.

Neuro-oncology
2025

Precocious Puberty in Children with Neurofibromatosis Type 1.

The Journal of pediatrics
2025

Clinical and MRI findings in patients with pediatric optic pathway glioma presenting with initial leptomeningeal dissemination.

Clinical radiology
2024

Optic pathway gliomas in children: Clinical characteristics, treatment, and outcome of 95 patients in a single center over a 31-year period. Can we avoid radiotherapy?

Pediatric blood &amp; cancer
2024

A nonsecreting suprasellar ectopic pituitary adenoma: A case report.

Radiology case reports
2024

Visual deterioration outcomes following optic pathway glioma treatment: a 12-year single institution retrospective study.

Journal of neuro-oncology
2024

Longitudinal changes in retinal ganglion cell function in optic pathway glioma evaluated by photopic negative response.

Experimental eye research
2024

Maternal obesogenic diet operates at the tumor cell of origin to increase incidence and decrease latency of neurofibromatosis type 1 optic pathway glioma.

Neuro-oncology
2024

Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.

PloS one
2024

Surgical options of chiasmatic hypothalamic glioma-a relevant part of therapy in an interdisciplinary approach for tumor control.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2024

An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.

Investigative ophthalmology &amp; visual science
2024

The role of surgery for optic pathway gliomas in the era of precision medicine.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2024

Low-grade glioma in children with neurofibromatosis type 1: surveillance, treatment indications, management, and future directions.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2024

DRI Triton SS-OCT applied to detect choroidal nodules in paediatric patients affected by NF1.

Heliyon
2024

NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.

Neuro-oncology
2024

Epidemiology and Outcomes of Neurofibromatosis Type 1 (NF-1): Multicenter Tertiary Experience.

Journal of multidisciplinary healthcare
2024

Is proton beam therapy always better than photon irradiation? Lessons from two cases.

Journal of medical radiation sciences
2024

Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.

Neuro-oncology
2024

Challenges in treating children with optic pathway gliomas: an 18-year experience from a middle-income country.

Frontiers in oncology
2024

The management of neurofibromatosis type 1 (NF1) in children and adolescents.

Expert review of neurotherapeutics
2024

Acquired myelinated retinal nerve fiber layer in a child with neurofibromatosis 1-related optic pathway glioma.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2024

Ophthalmologic Findings in Children with Neurofibromatosis Type 1.

Neuro-ophthalmology (Aeolus Press)
2024

Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.

Journal of neuro-oncology
2024

Arterial spin labelling: predictive role in surgical bleeding of paediatric optic pathway gliomas.

Clinical radiology
2024

Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1-Developmental and epileptic encephalopathy and optic pathway glioma.

Epileptic disorders : international epilepsy journal with videotape
2023

Optic Pathway Gliomas in Pediatric Population-Current Approach in Diagnosis and Management: Literature Review.

Journal of clinical medicine
2024

Prechiasmatic Transection of the Unilateral Dodge Class Ⅰ Optic Pathway Glioma without Neurofibromatosis Type 1: Technical Description and Clinical Prognosis.

World neurosurgery
2023

The Neuroimmune Regulation and Potential Therapeutic Strategies of Optic Pathway Glioma.

Brain sciences
2023

The Present and Future of Optic Pathway Glioma Therapy.

Cells
2023

An Isolated Case of Unilateral Macro-Ophthalmia With Resultant Anisometropic Amblyopia in Neurofibromatosis 1.

Cureus
2023

The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis.

Journal of neuro-oncology
2023

Optic Pathway Gliomas: The Trends of Basic Research to Reduce the Impact of the Disease on Visual Function.

Advances and technical standards in neurosurgery
2023

Visual outcomes after bevacizumab-based therapy for optic pathway glioma.

Pediatric blood &amp; cancer
2023

Long-term outcomes of symptomatic optic pathway glioma: 32-year experience at a single Western Australian tertiary pediatric oncology center.

Frontiers in oncology
2023

Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.

Cancer management and research
2023

Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.

European review for medical and pharmacological sciences
2023

Endoscopic debulking canalization for optic pathway glioma with obstructive hydrocephalus.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2023

An unusual presentation of bilateral optic pathway glioma in Crouzon Syndrome.

Pediatric hematology and oncology
2023

Neurosurgical morbidity in pediatric supratentorial midline low-grade glioma: Results from the German LGG studies.

International journal of cancer
2023

Transorbital neuroendoscopy-assisted resection of a giant optic pathway glioma in a neonate.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2023

Phenotype and Genotype of Saudi Pediatric Patients With Neurofibromatosis Type 1: A Seven-Year Multicenter Experience From Saudi Arabia.

Cureus
2023

[Characteristics of primary ocular symptoms in children with optic pathway glioma at different ages].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
2023

Cost Analysis of Orthoptist-Led Neurofibromatosis Type 1 Screening Clinics.

The British and Irish orthoptic journal
2023

A new era for optic pathway glioma: A developmental brain tumor with life-long health consequences.

Frontiers in pediatrics
2023

Spontaneous regression of tumor in a girl with optic pathway glioma with diencephalic syndrome.

Pediatric investigation
2023

Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.

Neuro-oncology
2023

Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma.

Cancers
2023

Neurosurgical management of proton beam therapy-induced moyamoya syndrome.

Journal of neurosurgery. Pediatrics
2023

The role of visual electrodiagnostics in management of children with neurofibromatosis type 1.

Documenta ophthalmologica. Advances in ophthalmology
2022

Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study.

Cancers
2022

Secondary Narcolepsy as Worsening Sign in a Pediatric Case of Optic Pathway Glioma.

Children (Basel, Switzerland)
2023

Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.

Hormones (Athens, Greece)
2023

A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes.

Neuro-oncology
2022

Management of Optic Pathway Glioma: A Systematic Review and Meta-Analysis.

Cancers
2022

Novel treatments in optic pathway gliomas.

Frontiers in ophthalmology
2022

Optical Coherence Tomography Significance in Managing Early Onset of Optic Pathway Gliomas in Children Younger than 5 Years of Age-A Retrospective Study.

Children (Basel, Switzerland)
2022

Systematic Review of Pediatric Brain Tumors in Neurofibromatosis Type 1: Status of Gene Therapy.

Cureus
2022

Current update on the visual outcome of optic pathway glioma associated with neurofibromatosis type-1.

Frontiers in surgery
2022

Trans-eyebrow supraorbital endoscope-assisted keyhole approach to suprasellar meningioma in pediatric patient: case report and literature review.

Chinese neurosurgical journal
2021

Disseminated craniospinal low-grade glioma in a patient with NF-1 without optic pathway pathology: illustrative case.

Journal of neurosurgery. Case lessons
2022

A Single-Center Treatment Experience of Gamma Knife Radiosurgery for Optic Pathway Glioma.

BioMed research international
2022

Glioma of the optic nerve and chiasm: a case report.

Arquivos brasileiros de oftalmologia
2022

Pilocytic astrocytoma of the optic nerve with intracystic hemorrhage in an adult: illustrative case.

Journal of neurosurgery. Case lessons
2022

Clinical Outcome of Optic Pathway and Hypothalamic Gliomas: A 20-Year Single-Institution Retrospective Study.

World neurosurgery
2022

Prospective registration of symptoms and times to diagnosis in children and adolescents with central nervous system tumors: A study of the Swedish Childhood Cancer Registry.

Pediatric blood &amp; cancer
2022

Corrigendum: The Visual Acuity Outcome and Relevant Factors Affecting Visual Improvement in Pediatric Sporadic Chiasmatic-Hypothalamic Glioma Patients Who Received Surgery.

Frontiers in neurology
2022

Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2022

Neurosurgery for Optic Pathway Glioma: Optimizing Multidisciplinary Management.

Frontiers in surgery
2022

Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1.

Frontiers in surgery
2022

Novel "T-Dimension" Therapies for Pediatric Optic Pathway Glioma: A Timely, Targeted, and Tailored Treatment Trend.

Pediatric neurosurgery
2022

Monomodality versus Combined Therapy in Optic Pathway Gliomas-20-Year Experience from a Singapore Children's Hospital.

Frontiers in surgery
2023

Visual outcomes and predictors in optic pathway glioma: a single centre study.

Eye (London, England)
2022

Recent Update in Pharmacological Agents for Optic Pathway Glioma.

Brain tumor research and treatment
2022

Recent Updates on Radiation Therapy for Pediatric Optic Pathway Glioma.

Brain tumor research and treatment
2023

Optic pathway glioma and endocrine disorders in patients with and without NF1.

Pediatric research
2022

Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess.

Journal of clinical medicine
2022

Surgical Management of Pre-Chiasmatic Intraorbital Optic Nerve Gliomas in Children after Loss of Visual Function-Resection from Bulbus to Chiasm.

Children (Basel, Switzerland)
2021

A therapeutic window for preventive therapy in NF1-associated optic pathway glioma.

Molecular &amp; cellular oncology
2022

The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital.

Neuropediatrics
2022

Diencephalic Syndrome Due to Optic Pathway Gliomas in Pediatric Patients: An Italian Multicenter Study.

Diagnostics (Basel, Switzerland)
2022

Imaging Findings of Pediatric Orbital Masses and Tumor Mimics.

Radiographics : a review publication of the Radiological Society of North America, Inc
2022

Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas.

Pediatric blood &amp; cancer
2022

Epidemiology and Survival of Patients With Optic Pathway Gliomas: A Population-Based Analysis.

Frontiers in oncology
2022

A 40-Year Cohort Study of Evolving Hypothalamic Dysfunction in Infants and Young Children (<3 years) with Optic Pathway Gliomas.

Cancers
2022

The role of imaging features and resection status in the survival outcome of sporadic optic pathway glioma children receiving different adjuvant treatments.

Neurosurgical review
2021

Neurofibromatosis Type 1 Related Hydrocephalus.

Neurology India
2022

Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV
2022

Whole-body MRI evaluation in neurofibromatosis type 1 patients younger than 3 years old and the genetic contribution to disease progression.

Orphanet journal of rare diseases
2022

Segmenting pediatric optic pathway gliomas from MRI using deep learning.

Computers in biology and medicine
2022

Optical Coherence Tomography Identifies Visual Pathway Involvement Earlier than Visual Function Tests in Children with MRI-Verified Optic Pathway Gliomas.

Cancers
2022

Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.

Neuro-oncology
2021

Neurofibromatosis Type 1 in Children: A Single-Center Experience.

Turkish archives of pediatrics
2022

Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.

Journal of neuro-oncology
2021

Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1.

Neurology. Clinical practice
2022

[Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].

Journal francais d'ophtalmologie
2021

The diagnostic accuracy and prognostic value of OCT for the evaluation of the visual function in children with a brain tumour: A systematic review.

PloS one
2021

Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia.

Nature communications
2021

Neuroimaging Features of Optic Nerve Hemangioblastoma Identified by Conventional and Advanced Magnetic Resonance Techniques: A Case Report and Literature Review.

Frontiers in oncology
2021

Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.

Orphanet journal of rare diseases
2022

Regression and pseudoprogression of pediatric optic pathway glioma in patients treated with proton beam therapy.

Pediatric blood &amp; cancer
2021

Inhibition of ERK/MAPK signaling as potential therapy to prevent optic pathway glioma in infants with neurofibromatosis type 1.

Developmental cell
2021

Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review.

PloS one
2023

Novel Variants and Clinical Characteristics of 16 Patients from Southeast Asia with Genetic Variants in Neurofibromin-1.

Journal of pediatric genetics
2021

A Unique Case of Sporadic Optic Pathway Glioma in an Infant With Acute Nystagmus.

Cureus
2022

Visual Outcomes of Optic Pathway Glioma Treated With Chemotherapy in Neurofibromatosis Type 1.

Journal of pediatric ophthalmology and strabismus
2021

Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.

Developmental cell
2021

Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?

Neuro-oncology
2024

Postoperative hydrocephalus is a high-risk lethal factor for patients with low-grade optic pathway glioma.

British journal of neurosurgery
2021

Mutational spectrum of NF1 gene in 24 unrelated Egyptian families with neurofibromatosis type 1.

Molecular genetics &amp; genomic medicine
2021

Case Report: Chemotherapy Indication in a Case of Neurofibromatosis Type 1 Presenting Optic Pathway Glioma: A One-Year Clinical Case Study Using Differential Tractography Approach.

Frontiers in human neuroscience
2021

Early radiotherapy preserves vision in sporadic optic pathway glioma.

Cancer
2021

Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Current oncology reports
2021

A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.

Neuro-oncology
2020

Resolving mystery behind autonomous retrogression of low-grade gliomas: A systematic review.

JPMA. The Journal of the Pakistan Medical Association
2020

Clinical spectrum of neurofibromatosis type 1 among children in a tertiary care center.

Neurosciences (Riyadh, Saudi Arabia)
2020

C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.

Cell transplantation
2020

Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.

NeuroImage. Clinical
2020

The Visual Acuity Outcome and Relevant Factors Affecting Visual Improvement in Pediatric Sporadic Chiasmatic-Hypothalamic Glioma Patients Who Received Surgery.

Frontiers in neurology
2020

Predicting pediatric optic pathway glioma progression using advanced magnetic resonance image analysis and machine learning.

Neuro-oncology advances
2020

Malignant optic nerve glioma in a young woman with 7 year follow up without recurrence.

American journal of ophthalmology case reports
2020

Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.

Diagnostics (Basel, Switzerland)
2020

Visual function tests including the role of optical coherence tomography in neurofibromatosis 1.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2020

Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.

Neuro-oncology advances
2020

NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation.

Neuro-oncology advances
2021

NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat.

Neuro-oncology
2020

Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients-Report from the German SIOP-LGG 2004 cohort.

International journal of cancer
2020

Neurofibromatosis 1-associated optic pathway gliomas.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2020

Intraoperative visual evoked potential monitoring for optic pathway glioma in an infant: A case description.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2020

Neurofibromatosis type 1-related hydrocephalus: causes and treatment considerations.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2020

Retrospective Multicentric Study on Non-Optic CNS Tumors in Children and Adolescents with Neurofibromatosis Type 1.

Cancers
2020

Homonymous Retinal Ganglion Cell Layer Atrophy With Asymptomatic Optic Tract Glioma in Neurofibromatosis Type I.

Frontiers in neurology
2020

Nonoptic pathway tumors in children with neurofibromatosis type 1.

Neurology
2020

Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.

The Journal of clinical endocrinology and metabolism
2021

Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.

American journal of ophthalmology
2020

Visual field fluctuations correlating with the menstrual cycle in a patient with optic pathway glioma.

BMJ case reports
2020

Optic pathway glioma with intraocular extension in a child with neurofibromatosis type-1.

Journal francais d'ophtalmologie
2020

Expanded transnasal approaches to the skull base in the Middle East: Where do we stand?

Annals of Saudi medicine
2020

3 Tesla MRI brain scanning under general anaesthesia in a paediatric 3 Tesla-compatible cochlear implant recipient, first reported case: Clinical considerations and implications for future practice.

International journal of pediatric otorhinolaryngology
2020

Neuropsychological outcomes of children with Optic Pathway Glioma.

Scientific reports
2021

Role of visual evoked potentials and optical coherence tomography in the screening for optic pathway gliomas in patients with neurofibromatosis type I.

European journal of ophthalmology
2019

[Effect of bevacizumab in treatment of children with optic pathway glioma].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2020

Radiation-Induced Moyamoya Syndrome in Children with Brain Tumors: Case Series and Literature Review.

World neurosurgery
2019

Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort.

Cancers
2019

Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations.

Cancers
2019

Brain Tumors in NF1 Children: Influence on Neurocognitive and Behavioral Outcome.

Cancers
2019

Lymphocyte Subpopulations in Patients With Neurofibromatosis Type 1-associated Optic Pathway Gliomas and Plexiform Neurofibromas.

Anticancer research
2020

Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2019

Assessment of the visual pathways in patients with neurofibromatosis-1 by 3S-space technique with 3-Tesla MRI.

Turkish journal of medical sciences
2019

Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience.

Postgraduate medicine
2019

Neurological malignancies in neurofibromatosis type 1.

Current opinion in oncology
2019

Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma.

Journal of neuro-oncology
2020

Rare Case of Sporadic Malignant Optic Pathway Glioma in 71-Year-Old Woman.

World neurosurgery
2019

68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma.

European journal of nuclear medicine and molecular imaging
2019

Central and peripheral steady-state visual evoked potentials in children with optic pathway gliomas.

Documenta ophthalmologica. Advances in ophthalmology
2019

Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1.

Endocrine journal
2019

Infantile Optic Pathway Glioblastoma.

World neurosurgery
2019

Neurofibromatosis Type 1-Related Hydrocephalus: Treatment Options and Considerations.

World neurosurgery
2018

Retinal Vascular and Neural Remodeling Secondary to Optic Nerve Axonal Degeneration: A Study Using OCT Angiography.

Ophthalmology. Retina
Ver todos os 211 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Glioma das vias ópticas.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Glioma das vias ópticas

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Differences in Optic Pathway Glioma Prevalence among Children with Neurofibromatosis Type 1.
    The Journal of pediatrics· 2026· PMID 41856269mais citado
  2. Central Precocious Puberty and Optic Pathway Glioma in Children with Neurofibromatosis 1: Associations with Tumor Location, Vision, and Treatment.
    The Journal of pediatrics· 2026· PMID 41780670mais citado
  3. Frontotemporal-orbitozygomatic approach for pediatric cranio-orbital tumors: a single-center experience.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery· 2026· PMID 41870661mais citado
  4. Using Optical Coherence Tomography in Pediatric Neuro-ophthalmology.
    International ophthalmology clinics· 2026· PMID 41870104mais citado
  5. Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes.
    Children (Basel, Switzerland)· 2026· PMID 41749521mais citado
  6. Progressive cervicothoracic meningocele with neurovascular compression and spinal deformity in neurofibromatosis type 1: a decade-long radiological and clinical evolution with operative repair. Illustrative case.
    J Neurosurg Case Lessons· 2026· PMID 41974064recente
  7. Coexisting Optic Pathway and Posterior Fossa Gliomas in an Adult With Previously Undiagnosed Neurofibromatosis Type 1.
    Cureus· 2026· PMID 41943761recente
  8. Dynamic contrast-enhanced magnetic resonance imaging in paediatric brain tumours systematically reviewed.
    Pediatr Radiol· 2026· PMID 41920352recente
  9. Extended endoscopic endonasal transplanum-transtuberculum surgery for optic pathway-hypothalamic glioma presenting with tonsillar herniation and syringomyelia: illustrative case.
    J Neurosurg Case Lessons· 2026· PMID 41911600recente
  10. Pediatric orbital masses from a tertiary pediatric oncology referral center: clinical characteristics and survival outcomes from a 20-year single-center experience.
    BMC Pediatr· 2026· PMID 41896783recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:2086(Orphanet)
  2. MONDO:0016167(MONDO)
  3. GARD:4107(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Q7936613(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Glioma das vias ópticas
Compêndio · Raras BR

Glioma das vias ópticas

ORPHA:2086 · MONDO:0016167
Prevalência
Unknown
Herança
Not applicable
CID-10
D33.3 · Neoplasia benigna dos nervos cranianos
CID-11
Ensaios
5 ativos
Medicamentos
5 registrados
Início
All ages
Prevalência
0.0 (Europe)
MedGen
UMLS
C0796418
Repurposing
1 candidato
5-aminolevulinic-acidoxidizing agent
EuropePMC
Wikidata
Papers 10a
Evidência
🥇 Rev. sistemática
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades